AIM ImmunoTech To Present Pre-Clinical Data On Potential Role Of Its Lead Drug Ampligen For Ebola Virus Treatment
Benzinga Newsdesk 5 months ago
News
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced it will release an on-demand video presentation detailing important previously published pre-clinical findings supporting the potential role of its lead drug Ampligen® (rintatolimod) as a prophylactic and/or an early-onset antiviral treatment for Ebola virus disease (EVD).